Investment Strategy
| The Nuveen Symphony All-Cap Core Fund is for investors seeking long-term capital appreciation. |
Who should invest
For investors who are seeking:
| - Long-term total return potential from a core equity investing strategy
- Exposure to stocks with a wide range of capitalizations
|
|
Fund Basics: Shares
Select Share Class:
A | C | I† | R3
| Fund Symbol | NACAX |
| Fund Cusip | 67065W621 |
| Inception Date | 5/31/2006 |
| Latest NAV as of 11/19/2009 | $16.66 |
| Fund Symbol | |
| Fund Cusip | |
| Inception Date | |
| Latest NAV as of | |
| Fund Symbol | NACCX |
| Fund Cusip | 67065W597 |
| Inception Date | 5/31/2006 |
| Latest NAV as of 11/19/2009 | $16.23 |
| Fund Symbol | NCCRX |
| Fund Cusip | 670725647 |
| Inception Date | 5/05/2009 |
| Latest NAV as of 11/19/2009 | $16.74 |
| Fund Symbol | NSAIX |
| Fund Cusip | 67065W589 |
| Inception Date | 5/31/2006 |
| Latest NAV as of 11/19/2009 | $16.79 |
|
A Word On Risk
| An investment in the Fund is subject to market risk or the risk that stocks in the portfolio will decline in response to such factors as adverse company news or industry developments or a general economic decline. Investments in small and mid cap companies are subject to greater volatility and price fluctuations. As with any mutual fund, possible loss of principal is a risk of investing. |
|
|
Portfolio Manager
|
|
| David Wang - Director of Equity Securities at Symphony. David's responsibilities also include design, research and implementation of Symphony's long-only equity strategies. David joined Symphony in 1994 from BARRA, Inc., where he was a member of the Active Strategies Group. At BARRA, he was responsible for investment strategy research, portfolio construction and rebalancing of several domestic and global equity funds. David received his MBA from the University of Illinois at Urbana-Champaign and holds a BS degree in Chemical Engineering from Tamkang University in Taipei. | |
|
|
|
|
† Effective May 1, 2008, Class R shares were renamed Class I shares. See the Fund's prospectus for more information.
|
|
|
|
|